- ViiV Healthcare, the joint venture between GlaxoSmithKline (NYSE:GSK) and Pfizer (NYSE:PFE), secures a manufacturing agreement with Shanghai-based Desano Pharmaceuticals for the production of dolutegravir in China. The deal provides an additional source of the dolutegravir active pharmaceutical ingredient and will allow ViiV to offer a competitive supply of Tivicay (dolutegravir 50 mg) in China and certain developing countries, subject to local approvals.
- Dolutegravir is an integrase strand transfer inhibitor that is used, in combination with other antiretroviral agents, to treat HIV infection. Integrase inhibitors block HIV replication by preventing the viral DNA from integrating into the genetic material of human immune cells (T cells).